Eloxx Pharmaceuticals, Inc. (ELOX)
|Net Income (ttm)||-57.50M|
|Day's Range||1.52 - 1.57|
|52-Week Range||1.18 - 6.77|
|Price Target||3.77 (+146.4%)|
|Est. Earnings Date||Nov 4, 2021|
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. [Read more...]
Financial PerformanceFinancial Statements
According to 4 analysts, the average rating for ELOX stock is "Buy." The 12-month stock price forecast is 3.77, which is an increase of 146.41% from the latest price.
Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights
WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Cap...
The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc's (NASDAQ: ELOX) ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in ...
Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)
Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LON...
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021
With July 4th on the way, which penny stocks are you watching right now? The post 7 Reddit Penny Stocks to Watch For the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information |...
Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.
Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwrit...
WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the c...
Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported ...
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the p...
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor)
Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) has acquired Zikani Therapeutics Inc in an all-stock transaction. The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare disease...
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business...
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year
Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on Ma...
Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a b...
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Develo...
Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology
Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients” Publication titled: “Phase 1 Renal Impairment Trial Resul...
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support f...
The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel
Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics ...